Platform
Products
- Digistain Breast
Partners
Investors
About
- About Digistain
- Team
News
Contact

✕

Platform
Products
- Digistain Breast
Partners
Investors
About
- About Digistain
- Team
News
Contact

Digistain works with CORE Diagnostics (India)

Home
News
News
Digistain works with CORE Diagnostics (India)

DIGISTAIN CLINICAL VALIDATION STUDY PUBLISHED IN ‘BREAST CANCER RESEARCH & TREATMENT’

January 24, 2024

EIT Health Finalist

September 4, 2024

DIGISTAIN CLINICAL VALIDATION STUDY PUBLISHED IN ‘BREAST CANCER RESEARCH & TREATMENT’

January 24, 2024

EIT Health Finalist

September 4, 2024

September 4, 2024

Categories

News

Tags

1713591561255

Share

Related posts

November 3, 2026

Digistain nominated for the EIT Awards 2026

November 3, 2026

Digistain at On Targeted Molecular Oncology 2026, Ankara

November 3, 2026

The Future Health Dialogue, Abu Dhabi

Comments are closed.

Digistain is a cancer biomarker company. Its breast cancer recurrence-risk test measures the tumour’s biochemistry directly, with results before the next appointment.

LRQA certified ISO 13485

Platform

Overview
How it works
Research and pipeline
Publications

Digistain Breast

Overview
For clinicians
For laboratories
For patients

Company

Partners
Investors
About
Team
News
Contact

© 2026 Digistain Ltd · ISO 13485:2016 certified (LRQA) for the design and development of IVD software used in cancer management · Privacy policy · Terms and conditions · Cookie policy